NCT05874570 is a Phase 4 clinical trial of Esomeprazole in Helicobacter Pylori Infection, sponsored by Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT05874570?

NCT05874570 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT05874570?

Interventions in NCT05874570: Esomeprazole, Bismuth Potassium Citrate, Tetracycline, Doxycycline, Metronidazole.

What condition does NCT05874570 study?

NCT05874570 studies Helicobacter Pylori Infection.

Is NCT05874570 still recruiting?

NCT05874570 is currently recruiting now. Last updated 30 December 2024.

Last reviewed 2024-12-30 · How we verify

NCT05874570

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Doxycycline for Helicobacter Pylori Rescue Treatment

Recruiting now Phase 4 Last updated 30 December 2024

What this trial tests

Phase 4 trial testing Esomeprazole in Helicobacter Pylori Infection in 368 participants. Currently enrolling.

Timeline

20 June 2023

Primary endpoint
10 October 2025

31 October 2025

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	368
Start date	20 June 2023
Primary completion	10 October 2025
Estimated completion	31 October 2025
Sites	1 location across China

Drugs / interventions tested

Esomeprazole (esomeprazole) — full drug profile →
Bismuth Potassium Citrate — full drug profile →
Tetracycline — full drug profile →
Doxycycline (doxycycline) — full drug profile →
Metronidazole (METRONIDAZOLE) — full drug profile →

Conditions studied

Helicobacter Pylori Infection — all drugs for Helicobacter Pylori Infection →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 70, any sex, with Helicobacter Pylori Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy. However, tetracycline is clinically unavailable in China and the high frequency of adverse events of bismuth quadruple therapy often result in poor compliance, which limited the applicability of this recommendation. This study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy in which tetracycline was replaced by doxycycline.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Esomeprazole

Trials testing the same drug.

NCT07399054 — Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU · not yet recruiting
NCT07018635 — A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Adm · Phase 1 · completed
NCT07268820 — Heartburn, Gastroesophageal Reflux Disease · Phase 4 · recruiting
NCT06851468 — Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori · NA · not yet recruiting
NCT06793943 — A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults · Phase 1 · completed

Other recruiting trials for Helicobacter Pylori Infection

Currently open trials in the same condition.

NCT07285096 — P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication · recruiting
NCT07358130 — Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy · NA · recruiting
NCT07165444 — Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatme · NA · recruiting
NCT06929962 — VA Dual Sequential Therapy · Phase 4 · recruiting
NCT06959368 — Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication · Phase 4 · recruiting

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05874570 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 30 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05874570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing